Introduction {#Sec1}
============

Immunoglobulin G4-related disease (IgG4-RD) was initially described in 2001 as sclerosing pancreatitis with elevated serum IgG4 levels^[@CR1]^, and has subsequently been described in various organ systems, including the biliary tree, salivary glands, periorbital tissues, kidneys, lungs, meninges, aorta, breast, prostate, thyroid gland, pericardium, skin, and lymph nodes^[@CR2]^. This is a fibro-inflammatory condition characterized by a tendency to form tumefactive lesions at multiple sites, with a distinctive histopathological appearance, and often, but not always, elevated serum IgG4 levels^[@CR2],[@CR3]^. Although glucocorticoids are effective and the standard therapy for IgG4-RD, the disease is known to be likely to relapse during tapering or cessation of the medicine. Yamamoto *et al*.^[@CR4]^ reported that more than half of patients with Mikulicz's disease experience relapse during steroid therapy. Thus, IgG4-RD has been deemed incurable in Japan, and investigators have attempted to elucidate its pathogenesis within the last decade.

There are many hypotheses regarding the pathogenesis of IgG4-RD that involve autoimmunity, molecular immunity, specific genotypes, intestinal bacterial flora, allergies, and other factors, which are yet to be proven. From a histopathological point of view, upregulation of T helper 2 (Th2) (interleukin \[IL\]-4, IL-5, and IL-13) and regulatory T (Treg) (IL-10 and transforming growth factor beta 1) cytokines was detected in affected tissues of patients with autoimmune pancreatocholangitis^[@CR5]^, suggesting that the immune reaction mediated by these cytokines may be responsible for the lesions. These findings have also been confirmed in salivary glands, ocular adnexa, and kidneys^[@CR6]--[@CR8]^. However, to the best of our knowledge, only a few previous reports have investigated the mechanism underlying Th2 and Treg activation in IgG4-RD.

We previously reported a significant upregulation of IL-4, IL-10, IL-13, and transforming growth factor beta 1 in IgG4-related submandibular gland disease^[@CR9]^. These findings in IgG4-related sialoadenitis were consistent with those of other previous reports^[@CR6],[@CR10],[@CR11]^. In addition, we discerned that the infiltrating cells expressing Th2 and Treg cytokines were histomorphologically similar to mast cells and exhibited strong cytoplasmic staining for immunoglobulin E (IgE). Interestingly, although the number of c-kit-positive mast cells was not significantly increased in IgG4-related submandibular gland disease as compared to that in sialolithiasis and normal submandibular glands, the number of strongly cytoplasmic IgE-positive mast cells was significantly increased in IgG4-related submandibular gland disease. Based on these findings, we note mast cells exhibiting strong cytoplasmic staining for IgE as a key role in IgG4-RD. However, the underlying mechanisms and immunological significance of strong cytoplasmic IgE staining remain unclear.

In this study, we aimed to confirm whether mast cells exhibiting strong cytoplasmic staining for IgE were noted in IgG4-related lymphadenopathy cases and to identify the significance of the strong cytoplasmic staining.

Materials and Methods {#Sec2}
=====================

Patients and samples {#Sec3}
--------------------

Tissue samples were obtained from 23 cases of IgG4-related lymphadenopathy. Tissue samples from an equal number of cases (*n* = 23) of non-specific lymphoid hyperplasia were used as disease controls. All slides were jointly reviewed by K.N., M.T., and Y.S. Formalin-fixed paraffin-embedded specimens were used for immunohistochemistry and dual immunofluorescence. All tissue samples were obtained with the approval of the Institutional Review Board of Okayama University (Okayama, Japan). Informed consent for the use of their samples in research was obtained from all patients.

Histological examination and immunohistochemistry {#Sec4}
-------------------------------------------------

The following methods were carried out in accordance with approved guidelines. All experimental protocols were approved by the Institutional Review Board at Okayama University.

Excisional biopsies were obtained from lymph node lesions in 23 patients with IgG4-related lymphadenopathy and an equal number of patients (*n* = 23) with non-specific lymphoid hyperplasia. The specimens were fixed in 10.0% formaldehyde and embedded in paraffin. Serial 4-µm-thick sections were cut from the paraffin-embedded tissue blocks and stained with hematoxylin and eosin. Sections were immunohistochemically stained using an automated Bond Max stainer (Leica Biosystems; Melbourne, Australia). The following primary antibodies were used: polyclonal IgG (dilution 1:20,000; Dako, Glostrup, Denmark), IgG4 (HP6025, dilution 1:10,000; The Binding Site, Birmingham, UK), KIT/CD117 (A4502, dilution 1:600; Dako), IgE (A094, dilution 1:500; Dako), and high affinity IgE receptor (FcεRI) (Ab54411, dilution 1:500; Abcam, Cambridge, UK). Following immunohistochemical staining, the number of IgG4- and IgG-positive cells were estimated in areas with the highest density of IgG4-positive cells. In accordance with the consensus statement on the pathological features of IgG4-RD^[@CR3]^, three different high power fields (HPFs) (eyepiece: ×10, lens: ×40) were examined to calculate the average number of IgG4-positive cells per HPF and the IgG4-positive/IgG-positive cell ratio. IgE- and FcεRI-positive cells were counted in three different HPFs (eyepiece: ×10, lens: ×20) that were determined to have the highest density of positive cells. The average number of positive cells per HPF was calculated.

Dual immunofluorescence assays {#Sec5}
------------------------------

For indirect dual immunofluorescence assays, paraffin sections were stained with the primary antibodies for IgE and FcεRI or FcεRI and c-kit. Fluorescein isothiocyanate-conjugated secondary antibodies (Alexa Fluor anti-mouse 555 and Alexa Fluor anti-rabbit 488; both from Life Technologies, Carlsbad, CA, USA) were used at a dilution of 1:400. The stained specimens were examined using a conventional immunofluorescence microscope (IX71; Olympus, Tokyo, Japan).

Statistical analysis {#Sec6}
--------------------

Data are presented as the means and standard deviations. All statistical analyses were performed using the Mann-Whitney *U* test in the Statistical Package for the Social Sciences for Windows, software version 14.0 (SPSS Inc., Chicago, IL, USA). A *P* \< 0.05 was considered statistically significant.

Results {#Sec7}
=======

Histological confirmation of IgG4-related lymphadenopathy {#Sec8}
---------------------------------------------------------

The clinicopathological characteristics of the patients with IgG4-related lymphadenopathy are summarized in Table [1](#Tab1){ref-type="table"}. The cohort was comprised of 14 men and 9 women, with a median age of 61 (range, 45--82) years. Post-biopsy serum IgG or IgG4 levels were obtained for all patients except for Patient 23. On initial clinical examination, 14 patients presented with localized cervical lymphadenopathy. Seven patients had additional areas of lymphadenopathy (≥2) and 9 patients had extranodal lesions (e.g., in the salivary and lacrimal glands). All patients were followed up with regular imaging, laboratory assays, and clinical examinations. The median follow-up period was 42 (range, 2--154) months. During follow-up, 10 patients (43%) exhibited relapse in the residual lymph nodes or their disease had progressed to the development of other lymph nodes or extranodal lesions, including those of the submandibular and lacrimal glands. The average number of IgG- and IgG4-positive cells was 224.1 (range: 85.7--378) and 259.1 (range: 97.7--437.3) per HPF, respectively. In all cases, the IgG4-positive/IgG-positive cell ratios were \>60.0%. The average numbers of IgE and FcεRI strongly cytoplasmic positive cells were 3.83 (range: 85.7--378) and 8.50 (range: 97.7--437.3) per HPF, respectively.Table 1Histological and serological findings of patients with IgG4-related lymphadenopathy.Case No.AgeSexLN site of biopsyLN size (mm)LocationExtranodal lesionAllergyRelapseIgG4+ cells (/HPF)IgG+ cells (/HPF)Histologically IgG4+/IgG+ cell ratio (%)IgE-count (HPF)FcεRI-count (/HPF)Serum-IgG4 (mg/dL)Serum-IgG (mg/dl)150MAxillary21Bilateral cervical, left axillary, paraaortic, mesenteric---Pollenosis, rhinitisYes277308.391.450.330.67158\*1930\*266MCervical16Bilateral cervical---NoneYes235266.387.54.335.3389\*1511\*350FCervical15Bilateral cervical, right infraclavicular---NoneNo218202112.20.33024\*n.e.445FCervical21Left cervical---Bronchilal asthmaNo186212.391.140.331.3318.3\*1202\*573FAbdominal30Paraaortic, mesenteric---DrugNo85.797.790.0511.6716.5\*1206651FCervical21Bilateral cervical---AsthmaYes261262.399.160.675.67223\*1425750MCervical23Right cervical---Allergic rhinitisYes245295.381.983517.8\*1072\*846MCervical13Left cervical---NoneNo241279.386.42013.6794.7\*1505\*971MCervical18Right cervical---Bronchilal asthmaNo378258152.21.671.6758.7\*644\*1067MCervical19Bilateral cervical, hilarRight lungAllergic rhinitisYes218297.773.835.3310.33389\*1619\*1158FCervical18Right cervicalBilateral parotid glands, left lobe of thyroid glandPollenosisNo18828278.763.6733.7251\*1297\*1261MCervical32Bilateral cervical---NoneYes364437.383.48313650\*2200\*1372MCervical20Left cervical, mediastinalRetroperitoneal fiborosis, sclerosing cholangitis, pituitary glandAsthmaYes23033968.7413.3323.671750\*n.e.1470MCervical10Bilateral cervicalParotid gland, bilateral lungsNoneNo173159.7108.95.674.33236\*1466\*1557FCervical6Left cervical, bilateral axillary, bilateral infraclavicular---NoneYes219346.365.021012.7\*1542\*1682FCervical28Bilateral cervical, bilateral axillary, hilarBilateral submandibular glands, bilateral lacrimal glands, orbit, right lungNoneYes26728394.4311.33n.e.4057\*1775FCervical27Left cervical---AsthmaNo199272.378.1711.6788.9\*n.e.1849MCervical28Left cervicalLeft submandibular glandNoneNo12016772.583.67998.2\*1000\*1972MCervical25Bilateral cervical---DrugNo220278.379.138.6711.6771.2\*1201.7\*2066MCervical12Right cervicalRight submandibular gland, left lobe of thyroid glandNoneYes251316.781.471.672.6783.3\*1188.6\*2157FCervical24Bilateral cervical, hilarBilateral submandibular glands, bilateral lacrimal glandsAsthmaNo218204110.942.6763020112254MAxillary35Right axillaryRight lungPollenosis, bronchial asthmaNo178161.3110.83.332.6745\*900\*2372MCervical24Cervical---NoneNo18223478.481533.667n.e.n.e.M; male, F; female, LN; lymph node, n.e.; not examined. \*; measurement of serum levels after biopsy.

We confirmed that the tissue specimens from all 23 cases with IgG4-RD showed typical histological features of progressively transformed germinal center (PTGC)-type IgG4-related lymphadenopathy (Fig. [1A--F](#Fig1){ref-type="fig"}).Figure 1Histological features of immunoglobulin G4 (IgG4)-related lymphadenopathy (Patient 19). (**A**) Lymph nodes showing multiple follicular hyperplasia with progressively transformed germinal centers (hematoxylin and eosin \[H&E\] staining, 20× magnification). (**B**) Irregular structure of a germinal center owing to the infiltration of small lymphocytes from the mantle zone (H&E staining, 100× magnification). (**C**) Abundant plasma cells infiltrating the germinal centers (H&E staining, 200× magnification). (**D**) Many eosinophils infiltrating the interfollicular zone (H&E staining, 200× magnification). (**E**,**F**) The majority of IgG4-positive plasma cells are localized in the germinal centers. The IgG4-positive/IgG-positive plasma cell ratio is \>70% (IgG4 and IgG immunostaining, 100× magnification).

Histological features of non-specific lymphoid hyperplasia {#Sec9}
----------------------------------------------------------

The specimens exhibited multiple lymphoid follicle formations with moderate lymphocytic infiltration of interfollicular areas. Compared to the histological features of IgG4-related lymphadenopathy, those of non-specific lymphoid hyperplasia showed no PTGC, and less infiltration of plasma cells and/or eosinophils. Dermatopathic and autoimmune disease-associated lymphadenopathies, including rheumatoid arthritis, systemic lupus erythematosus, and Sjögren's syndrome, were excluded.

Clinical summary {#Sec10}
----------------

The clinical differences between IgG4-related lymphadenopathy patients and those with non-specific lymphoid hyperplasia are shown in Table [2](#Tab2){ref-type="table"}. The median age was 61 (range, 45--82) years for IgG4-related lymphadenopathy and 65 (range, 18--81) for non-specific lymphoid hyperplasia (*P* = 0.369). The overall median age was 63 (range, 18--82). There was no significant difference in sex between the two groups (IgG4-related lymphadenopathy: 14 men and 9 women, non-specific lymphoid hyperplasia: 12 men and 11 women; *P* = 0.562). Patients with IgG4-related lymphadenopathy had larger lymph nodes than patients with non-specific lymphoid hyperplasia (mean length, 21.1 \[range, 6.0--35.0\] *vs*. 12.3 \[range, 5.0--26.0\] mm, respectively; *P* \< 0.001). Lymphadenopathy occurred in the cervical region in 21 patients with IgG4-related lymphadenopathy and in 10 patients with non-specific lymphoid hyperplasia (91.3% *vs*. 43.5%, respectively; *P* \< 0.001).Table 2Clinical characteristics of IgG4-related lymphadenopathy and non-specific lymphoid hyperplasia.IgG4-related lymphadenopathyNon-specific lymphoid hyperplasia*P*Number2323---Age, years61.5 (45--82)57.3 (15--81)0.37Gender; male (%)14 (60.9%)12 (52.2%)0.56Size of lymph node (mm)21.1 (6--35)12.3 (5--26)0.000025Site of lymph node Cervical21 (91.3%)10 (43.5%)0.00038 Axillary4 (17.4%)6 (26.1%)0.49 Supraclavicular3 (13.0%)1 (0.043%)0.31 Hilar4 (17.4%)1 (0.043%)0.16 Inguinal0 (0%)5 (21.7%)0.022 Multiple8 (34.8%)6 (26.1%)0.53 Extranodal lesion9 (39.1%)------(salivary gland, lacrimal gland, lung, etc.)

IgE and FcεRI staining patterns in IgG4-related lymphadenopathy {#Sec11}
---------------------------------------------------------------

A large number of IgE- and FcεRI-positive cells were detected in the tissues of patients with IgG4-related lymphadenopathy and non-specific lymphoid hyperplasia (Supplementary Figures [1](#MOESM1){ref-type="media"} and [2](#MOESM1){ref-type="media"}). In the non-specific lymphoid hyperplasia specimens, most mast cells stained for IgE and FcεRI with a surface membrane pattern (Figs [2A](#Fig2){ref-type="fig"} and [3A](#Fig3){ref-type="fig"}). In contrast, in the IgG4-related lymphadenopathy specimens, some mast cells stained for IgE and FcεRI with a strongly cytoplasmic pattern (Figs [2B](#Fig2){ref-type="fig"} and [3B](#Fig3){ref-type="fig"}). There was a greater number of strongly cytoplasmic IgE-positive cells in the IgG4-related lymphadenopathy specimens than in the non-specific lymphoid hyperplasia specimens (mean: 3.83 ± 3.99 *vs*. 1.20 ± 1.79 cells per HPF, respectively; *P* = 0.007) (Fig. [2C](#Fig2){ref-type="fig"}). Strongly cytoplasmic FcεRI-positive cells were also detected more frequently in the IgG4-related lymphadenopathy specimens than in the non-specific lymphoid hyperplasia specimens (mean: 7.14 ± 8.21 *vs*. 2.13 ± 3.03 cells per HPF, respectively; *P* = 0.011) (Fig. [3C](#Fig3){ref-type="fig"}).Figure 2Staining for immunoglobulin E (IgE). (**A**) Mast cells exhibiting moderate-to-week IgE staining and a membranous localization in non-specific lymphoid hyperplasia. (**B**) In contrast, mast cells exhibit strong cytoplasmic staining for IgE in immunoglobulin G4-related lymphadenopathy (Patient 19). (**C**) The number of strongly cytoplasmic IgE-positive cells is counted in each high power field and was significantly larger in immunoglobulin G4-related lymphadenopathy than in non-specific lymphoid hyperplasia (^\*^*P* \< 0.01).Figure 3Staining pattern of high affinity immunoglobulin E (IgE) receptor (FcεRI) is similar to that of IgE. (**A**) Infiltrating mast cells in non-specific lymphoid hyperplasia exhibit weak membranous FcεRI staining. (**B**) In contrast, infiltrating mast cells in immunoglobulin G4-related lymphadenopathy exhibit strong cytoplasmic staining (Patient 19). (**C**) Strongly cytoplasmic FcεRI-positive cells are significantly increased in immunoglobulin G4-related lymphadenopathy as compared to those in non-specific lymphoid hyperplasia (^\*^*P* = 0.01).

Dual immunofluorescence assay {#Sec12}
-----------------------------

In the IgG4-related lymphadenopathy specimens, IgE and FcεRI staining exhibited a cytoplasmic granular pattern (Fig. [4A,B](#Fig4){ref-type="fig"}). Intracytoplasmic granules stained positive for IgE (green) and FcεRI (red), some of which overlapped as yellow spots. In the non-specific lymphoid hyperplasia specimens, IgE and FcεRI stained the surface membrane. These cells were positive for c-kit.Figure 4Dual immunofluorescence of mast cells in immunoglobulin G4-related lymphadenopathy and non-specific lymphoid hyperplasia. (**A**) In immunoglobulin G4-related lymphadenopathy, both immunoglobulin E (IgE) and high affinity IgE receptor (FcεRI) exhibit a granular pattern, some of which overlap, resulting in yellow spots. In non-specific lymphoid hyperplasia, IgE stains the surface membrane, and FcεRI does not exhibit a granular pattern. (**B**) Staining for c-kit and FcεRI.

Discussion {#Sec13}
==========

Although many previous studies regarding IgG4-RD have been reported in the last decade, the pathogenesis of the disease remains unclear. Recent studies have reported that IgG4-RD is a Th2- and Treg-dominant disease, and the activation of these cytokines may be responsible for this disease^[@CR5],[@CR6],[@CR9],[@CR10],[@CR12]--[@CR15]^. However, studies investigating the mechanism underlying cytokine activation in IgG4-RD are few. In this study, we focused on mast cells exhibiting strong cytoplasmic staining for IgE.

Comprehensive diagnostic criteria consisted of elevated serum IgG4 concentrations (\>135 mg/dl), but not in all cases^[@CR3],[@CR16],[@CR17]^. Some patients with PTGC-type IgG4-related lymphadenopathy have normal serum IgG4 levels when measurements are obtained after biopsy, at which time there are no residual primary lesions^[@CR18]^. In our current data, serum IgG4 levels in 16 cases were \<135 mg/dl. Furthermore, the recurrence ratio of IgG4-RD has been reported at 21.3%^[@CR17]^. Some patients with PTGC-type IgG4-related lymphadenopathy have also experienced either persistence or relapse of residual lymph nodes^[@CR18]^. In this study, 10 of 23 patients progressed to the development of other lymph nodes or extranodal lesions with elevated levels of serum IgG4.

Here, we confirmed that mast cells exhibiting strong cytoplasmic staining for IgE, were increased in IgG4-related lymphadenopathy. This is consistent with our previous report of submandibular gland disease^[@CR9]^. Regarding the significance of strong cytoplasmic staining for IgE, we posit two hypotheses: overstaining and endocytosis.

IgG4-RD is frequently complicated by allergic conditions^[@CR19],[@CR20]^. We previously reported that 52% of patients with IgG4-related lymphadenopathy also had allergic disease^[@CR18]^. Our current study showed that 15 of 19 (78.9%) patients examined had allergic conditions. Furthermore, elevation of serum IgE levels, defined as IgE \>250 IU/ml, was observed in more than half of patients with IgG4-RD^[@CR17]^, suggesting that strong cytoplasmic staining for IgE might indicate only overstaining. However, this study confirmed that mast cells exhibiting strong cytoplasmic staining for FcεRI also increased, as did staining for IgE.

Recent reports have shown that the activation of mast cells leads to internalization of IgE and FcεRI^[@CR21],[@CR22]^. Accordingly, we added dual immunofluorescence assays, resulting in IgE and FcεRI staining exhibited as multiple cytoplasmic granules, some of which overlapped in IgG4-related lymphadenopathy. In contrast, staining in non-specific lymphoid hyperplasia was localized to the surface membrane. These results showed that the significance of strong cytoplasmic staining for IgE and FcεRI might reflect the internalization of IgE and FcεRI due to mast cell activation in IgG4-RD. Mast cells are activated by various biological substances (e.g., exogenous stimuli, endogenous peptides, chemokines, components of the complement system, and Fc receptors for IgE), leading to degranulation and the production of mediators such as cytokines and eicosanoids^[@CR23]^. Some previous studies have suggested that response to antigen presentation might be involved in the pathogenesis of IgG4-RD^[@CR20],[@CR24]--[@CR26]^. Our current study suggests that some antigens might activate mast cells. However, additional assays are needed to elucidate the functional significance of IgE and FcεRI internalization. Although previous reports clarified the internalized FcεRI trafficking in early endosomes^[@CR23]^, no published reports have investigated the trafficking completely.

Other Th subsets (T follicular helper cells or CD4+ cytotoxic T lymphocytes) and other immune cells (M2 macrophages) have recently been reported to participate in the pathogenesis of IgG4-RD^[@CR20],[@CR25],[@CR27]--[@CR29]^. Mattoo *et al*.^[@CR25]^ reported prominent clonal expansions of CD4+ SLAMF7+ cytotoxic T lymphocytes but not CD4+GATA3+ memory Th2 cells in patients with IgG4-RD. This strongly suggests that these cytotoxic T lymphocytes expanded in response to a specific causal antigen. Furukawa *et al*.^[@CR29]^. suggested that M2 macrophages producing IL-33 are deeply involved in the activation of Th2 immune responses in IgG4-RD. Therefore, IgG4-RD might progress via the interconnected network of various Th subsets or immune cells.

In conclusion, we confirmed that mast cells exhibiting strong cytoplasmic staining for IgE and FcεRI were increased in IgG4-related lymphadenopathy, implying the activation of mast cells. Since mast cells "communicate" with various cells to produce a mediator, a better understanding of the role of mast cells could enable us to understand the pathogenesis of IgG4-RD.
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